| TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
History of the Market
Immune System
Autoimmunity
Genetic Factors
Environmental Factors
Gene Research
Distribution
Technology
Demographics
CHAPTER THREE: MARKETS FOR RHEUMATOID ARTHRITIS
Overview
Description of Rheumatoid Arthritis
Diagnosis
Treatment Guidelines
Economic Impact of Disease
Trends in Insurance and Reimbursement
Description of products
Non-steroid Anti-inflammatory Drugs
Biologic Treatments
Disease Modifying Anti-rheumatic Drugs (DMARDs)
Immunosuppressant and Other Biologic Drugs
New Developments
Market Overview
Market by Product Type
Market by Geographical Region
Competitive Analysis
Corporate Profiles
Abbott Laboratories
Amgen, Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Centocor, Inc.
Genentech, Inc.
Merck & Company, Inc.
Novartis International AG
Pfizer, Inc.
Schering-Plough Corporation
Wyeth
CHAPTER FOUR: MARKETS FOR LUPUS ERYTHEMATOSUS
Overview
Description of Lupus Erythematosus
Diagnosis
Risk Factors
Treatment Guidelines
Economic Impact of Disease
Trends in Insurance and Reimbursement
Description of products
New Developments
Market Overview
Market by Product Type
Market by Geographical Region
Competitive Analysis
Corporate Profiles
Aspreva Pharmaceuticals Corporation
Bristol-Myers Squibb
Genelabs Technologies, Inc.
Genentech, Inc.
GlaxoSmithKline plc
Human Genome Sciences
La Jolla Pharmaceutical Company
Roche
UCB S.A.
CHAPTER FIVE: TOTAL MARKET SIZE AND FORECAST
Overview
Total Market Size and Forecast
Markets by Segments
Leading Competitors
CHAPTER SIX: LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: The World Market for Prescription Rheumatoid Arthritis
and Lupus Treatments, 2004-2011
Figure 1-1: The World Market for Prescription Rheumatoid Arthritis
and Lupus Treatments, 2004-2011
CHAPTER TWO: INTRODUCTION
Table 2-1: World Population by Selected Geographical Region,
2006-2050
Figure 2-1: World Population by Selected Geographical
Region, 2006-2050
Table 2-2: Estimated World Population by Age and Geographical Region, 2006
Table 2-2: Estimated World Population by Age and Geographical Region, 2006
CHAPTER THREE: RHEUMATOID ARTHRITIS MARKETS
Table 3-1: World Prevalence of Rheumatoid Arthritis by Region 25
Figure 3-1: World Prevalence of Rheumatoid Arthritis, Percent by Region
Table 3-2: Select Marketed Non-steroidal Anti-inflammatory Drugs
Table 3-3: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
Table 3-4: Selected Prescription Immunosuppressant and Other Biologic Drugs
Table 3-5: New Developments in Rheumatoid Arthritis
Figure 3-2: Number of New Developments for Rheumatoid Arthritis
by Development Phase
Table 3-6: The World Market for Prescription Rheumatoid Arthritis
Treatments, 2004-2011
Figure 3-3: The World Market for Prescription Rheumatoid Arthritis
Treatments, 2004-2011
Table 3-7: The World Market for Prescription Rheumatoid Arthritis
Treatments, by Product Type, 2004-2011
Figure 3-4:The World Market for Prescription Rheumatoid Arthritis
Treatments, by Product Type, 2004-2011
Figure 3-5: The World Market for Prescription Rheumatoid Arthritis
Treatments, by Product Type and Percent Distribution, 2004-2011
Figure 3-6: The World Market for Prescription Rheumatoid Arthritis
Treatments, by Percent and Product Type, 2006
Figure 3-7: The World Market for Prescription Rheumatoid Arthritis
Treatments, by Percent and Product Type, 2011
Table 3-8: The World Market for Prescription Rheumatoid Arthritis, by
Geographic Region, 2006
Figure 3-8: The World Market for Prescription Rheumatoid Arthritis,
by Geographic Region, 2006
Table 3-9: Leading Suppliers’ Shares of the World Market for Prescription
Rheumatoid Arthritis Treatments, 2006
Figure 3-9: Leading Suppliers’ Shares of the World Market for Prescription
Rheumatoid Arthritis Treatments, 2006
CHAPTER FOUR: LUPUS TREATMENT MARKETS
Table 4-1: World Prevalence of Lupus by Region
Figure 4-1: World Prevalence of Lupus, Percent by Region
Table 4-2: Select Marketed Non-steroidal Anti-inflammatory Drugs
Table 4-3: Selected Corticosteroids, Immunosuppressives and DMARDs
Table 4-4: New Developments in Lupus Erythrematosus
Figure 4-2: Number of New Developments for Lupus Erythrematosus by
Development Phase
Table 4-5: The World Market for Prescription Lupus Treatments, 2004-2011
Figure 4-3: The World Market for Prescription Lupus Treatments, 2004-2011
Table 4-6: The World Market for Prescription Lupus Treatments, by
Product Type, 2004-2011
Figure 4-4: The World Market for Prescription Lupus Treatments, by Product
Type, 2004-2011
Figure 4-5: The World Market for Prescription Lupus Treatments, by
Product Type and Percent Distribution, 2004-2011
Figure 4-6:The World Market for Prescription Lupus Treatments, by Percent
and Product Type, 2006
Figure 4-7:The World Market for Prescription Lupus Treatments, by Percent
and Product Type, 2011
Table 4-7:The World Market for Prescription Lupus Treatments, by
Geographic Region, 2006
Figure 4-8:The World Market for Prescription Lupus Treatments, by
Geographic Region, 2006
Table 4-8:Estimated Leading Suppliers’ Shares of the World Market for
Prescription Lupus Treatments, 2011
Figure 4-9:Estimated Leading Suppliers’ Shares of the World Market for
Prescription Lupus Treatments, 2011
CHAPTER FIVE: WORLD MARKET SUMMARY
Table 5-1:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, 2004-2011
Figure 5-1:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, 2004-2011
Table 5-2:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, by Product Type, 2004-2011
Figure 5-3:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, by Product Type, 2004-2011
Figure 5-4:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, by Product Type and Percent Distribution, 2004-2011
Figure 5-5:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, by Percent and Product Type, 2006
Figure 5-6:The World Market for Prescription Rheumatoid Arthritis and Lupus
Treatments, by Percent and Product Type, 2011 |
